Skip to main content
. 2023 Oct 30;14:1282824. doi: 10.3389/fgene.2023.1282824

FIGURE 1.

FIGURE 1

Prognostic tumor metabolic subtypes in pancreatic ductal adenocarcinoma (PDAC). (A) Unsupervised clustering (k = 2) illustrating distinct metabolic subgroups in the TCGA PDAC cohort (N = 142). The heatmap depicts expression levels of prognostic metabolic genes within the identified subtypes, highlighting both “lower-risk” (M1) and “high-risk” (M2) groups. (B,C) Kaplan-Meier plot displaying the overall and progression-free survival of the metabolic subtypes in the discovery cohort, demonstrating significant differences in survival outcomes. (D−F) Overall survival analysis of resectable PDAC patients: International Cancer Genome Consortium (ICGC, n = 172), Clinical Proteomic Tumor Analysis Consortium (CPTAC, n = 140), and unresectable patients from the COMPASS cohort (n = 272) stratified according to predicted metabolic subtypes. (G,H) Bar chart presents the responses to the first line treatment in COMPASS cohort. M1 subtype exhibits stable and partial responses to both FOLFIRINOX and Gemcitabine/Nab-paclitaxel. On the contrary, M2 group shows poor response to gemcitabine and combined therapy. Log-rank and Chi-square p-values are shown in the figure.